银华中证创新药产业ETF发起式联接C(012782)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-17,479,426.74 |
15,381,820.78 |
26,985,684.74 |
-18,772,756.82 |
| 利息合计 |
108,796.66 |
161,542.89 |
64,986.81 |
59,163.78 |
| 其中:存款利息收入 |
108,796.66 |
161,542.89 |
64,986.81 |
59,163.78 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-2,155,972.40 |
1,087,548.60 |
-4,344,849.51 |
-8,805,503.47 |
| 其中:股票投资收益 |
- |
- |
- |
- |
| 基金投资收益 |
-2,155,972.40 |
1,087,548.60 |
-4,344,849.51 |
-8,805,503.47 |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
- |
- |
- |
- |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-15,869,725.48 |
13,345,046.30 |
31,004,935.48 |
-10,169,799.75 |
| 其他收入 |
437,474.48 |
787,682.99 |
260,611.96 |
143,382.62 |
| 费用 |
337,166.87 |
457,304.94 |
190,649.08 |
255,516.19 |
| 管理人报酬 |
72,390.85 |
83,032.27 |
32,354.16 |
29,960.40 |
| 基金托管费 |
7,239.11 |
8,303.31 |
3,235.47 |
2,996.08 |
| 销售服务费 |
178,139.75 |
201,713.84 |
80,535.69 |
72,307.71 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
79,397.16 |
160,259.00 |
74,523.76 |
150,252.00 |
| 利润总额 |
-17,816,593.61 |
14,924,515.84 |
26,795,035.66 |
-19,028,273.01 |